David Azria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6000422/publications.pdf

Version: 2024-02-01

53 2,063 21 papers citations h-index

56 56 56 2722 all docs docs citations times ranked citing authors

45

g-index

#	Article	IF	Citations
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.6	10
2	Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study. Frontiers in Oncology, 2022, 12, 842402.	2.8	17
3	Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study. Cancers, 2022, 14, 1943.	3.7	8
4	Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review. Frontiers in Oncology, 2021, 11, 666962.	2.8	0
5	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.6	11
6	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy and Oncology, 2021, 159, 146-154.	0.6	37
7	Magnetic Resonance–Guided Reirradiation for Local Recurrence Within the Prostate or in the Prostate Bed: Preliminary Results of a Prospective Registry Study. Advances in Radiation Oncology, 2021, 6, 100748.	1.2	8
8	Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiotherapy and Oncology, 2021, 161, 95-114.	0.6	19
9	Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers, 2021, 13, 4853.	3.7	6
10	Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure. Radiotherapy and Oncology, 2020, 144, 141-147.	0.6	22
11	Use of genomics to balance cure and complications. Nature Reviews Clinical Oncology, 2020, 17, 9-10.	27.6	O
12	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	2.8	15
13	Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. International Journal of Radiation Oncology Biology Physics, 2020, 106, 1039-1051.	0.8	10
14	Intraoperative partial irradiation for highly selected patients with breast cancer: Results of the INTRAOBS prospective study. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 114-119.	1.4	10
15	Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiation Oncology, 2019, 14, 142.	2.7	8
16	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 76-85.	4.4	9
17	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
18	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. Cancers, 2019, 11, 802.	3.7	24

#	Article	IF	CITATIONS
19	Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. International Journal of Radiation Oncology Biology Physics, 2019, 104, 365-373.	0.8	26
20	A Wake-Up Call for Routine Morbidity and Mortality Review Meeting Procedures as Part of a Quality Governance Programs in Radiation Therapy Departments: Results of the PROUST Survey. Practical Radiation Oncology, 2019, 9, 108-114.	2.1	9
21	Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD. Computer Methods and Programs in Biomedicine, 2018, 158, 153-159.	4.7	5
22	In Regard to Pereira etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 101, 490-491.	0.8	1
23	Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator. Frontiers in Oncology, 2018, 8, 83.	2.8	5
24	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. European Journal of Human Genetics, 2018, 26, 1732-1742.	2.8	44
25	Evaluation of reproducibility of tumor repositioning during multiple breathing cycles for liver stereotactic body radiotherapy treatment. Reports of Practical Oncology and Radiotherapy, 2017, 22, 132-140.	0.6	15
26	T lymphocytes to predict radiation-induced late effects in normal tissues. Expert Review of Molecular Diagnostics, 2017, 17, 119-127.	3.1	19
27	Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. Reports of Practical Oncology and Radiotherapy, 2017, 22, 141-149.	0.6	12
28	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	2.8	36
29	One Size Fits All: Does the Dogma Stand in Radiation Oncology?. EBioMedicine, 2016, 10, 19-20.	6.1	2
30	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I–II trials. Radiotherapy and Oncology, 2016, 121, 193-198.	0.6	36
31	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98
32	Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. EBioMedicine, 2015, 2, 1965-1973.	6.1	87
33	Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients. Radiation Oncology, 2015, 10, 209.	2.7	8
34	Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Critical Reviews in Oncology/Hematology, 2015, 93, 312-319.	4.4	20
35	Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. Critical Reviews in Oncology/Hematology, 2015, 94, 270-278.	4.4	5
36	Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer. International Journal of Molecular Sciences, 2014, 15, 8138-8152.	4.1	4

#	Article	lF	Citations
37	Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of aÂPhase 1 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 853-859.	0.8	21
38	Intraoperative radiotherapy for breast cancer. Lancet, The, 2014, 383, 578-581.	13.7	12
39	In Regard to Foro etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 470.	0.8	2
40	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.8	99
41	Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial. Radiation Oncology, 2013, 8, 191.	2.7	41
42	Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Review of Proteomics, 2013, 10, 33-42.	3.0	48
43	Simultaneous integrated boost plan comparison of volumetricâ€modulated arc therapy and sliding window intensityâ€modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer. Journal of Applied Clinical Medical Physics, 2013, 14, 26-35.	1.9	19
44	Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiation Oncology, 2012, 7, 77.	2.7	172
45	Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiation Oncology, 2011, 6, 147.	2.7	13
46	Intraoperative Radiotherapy in Early-Stage Breast Cancer: Results of the Montpellier Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2010, 76, 698-703.	0.8	87
47	Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiation Oncology, 2010, 5, 92.	2.7	62
48	Partial breast irradiation: new standard for selected patients. Lancet, The, 2010, 376, 71-72.	13.7	24
49	Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncology, The, 2010, 11, 258-265.	10.7	105
50	Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review. Journal of Clinical Oncology, 2009, 27, 2269-2277.	1.6	221
51	Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy. Clinical Cancer Research, 2008, 14, 6284-6288.	7.0	136
52	Intraoperative radiotherapy given as a boost for early breast cancer: Long-term clinical and cosmetic results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1410-1415.	0.8	103
53	CD4 and CD8 T-Lymphocyte Apoptosis Can Predict Radiation-Induced Late Toxicity: A Prospective Study in 399 Patients. Clinical Cancer Research, 2005, 11, 7426-7433.	7.0	198